Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Identifieur interne : 000087 ( PubMed/Corpus ); précédent : 000086; suivant : 000088Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
Auteurs : Michel Delforge ; Leonard Minuk ; Jean-Claude Eisenmann ; Bertrand Arnulf ; Letizia Canepa ; Alberto Fragasso ; Serge Leyvraz ; Christian Langer ; Yousef Ezaydi ; Dan T. Vogl ; Pilar Giraldo-Castellano ; Sung-Soo Yoon ; Charles Zarnitsky ; Martine Escoffre-Barbe ; Bernard Lemieux ; Kevin Song ; Nizar Jacques Bahlis ; Shien Guo ; Mara Silva Monzini ; Annette Ervin-Haynes ; Vanessa Houck ; Thierry FaconSource :
- Haematologica [ 1592-8721 ] ; 2015.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (administration & dosage), Cross-Sectional Studies, Dexamethasone (administration & dosage), Female, Health Status, Humans, Male, Melphalan (administration & dosage), Multiple Myeloma (diagnosis), Multiple Myeloma (drug therapy), Multiple Myeloma (psychology), Prednisone (administration & dosage), Quality of Life (psychology), Thalidomide (administration & dosage), Thalidomide (analogs & derivatives).
- MESH :
- chemical , administration & dosage : Dexamethasone, Melphalan, Prednisone, Thalidomide.
- administration & dosage : Antineoplastic Combined Chemotherapy Protocols.
- chemical , analogs & derivatives : Thalidomide.
- diagnosis : Multiple Myeloma.
- drug therapy : Multiple Myeloma.
- psychology : Multiple Myeloma, Quality of Life.
- Aged, Aged, 80 and over, Cross-Sectional Studies, Female, Health Status, Humans, Male.
Abstract
We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexamethasone, and melphalan, prednisone, thalidomide improved patients' health-related quality-of-life from baseline over the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalidomide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeated-measures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and low-dose dexamethasone delays disease progression versus melphalan, prednisone, thalidomide and has been associated with a clinically meaningful improvement in health-related quality-of-life. These results further establish continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone, thalidomide.
DOI: 10.3324/haematol.2014.120121
PubMed: 25769541
Links to Exploration step
pubmed:25769541Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.</title><author><name sortKey="Delforge, Michel" sort="Delforge, Michel" uniqKey="Delforge M" first="Michel" last="Delforge">Michel Delforge</name><affiliation><nlm:affiliation>Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium michel.delforge@uzleuven.be.</nlm:affiliation></affiliation></author><author><name sortKey="Minuk, Leonard" sort="Minuk, Leonard" uniqKey="Minuk L" first="Leonard" last="Minuk">Leonard Minuk</name><affiliation><nlm:affiliation>London Health Sciences Centre, London, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Eisenmann, Jean Claude" sort="Eisenmann, Jean Claude" uniqKey="Eisenmann J" first="Jean-Claude" last="Eisenmann">Jean-Claude Eisenmann</name><affiliation><nlm:affiliation>Hôpital Emile Muller, Mulhouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Arnulf, Bertrand" sort="Arnulf, Bertrand" uniqKey="Arnulf B" first="Bertrand" last="Arnulf">Bertrand Arnulf</name><affiliation><nlm:affiliation>Hôpital Saint-Louis, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Canepa, Letizia" sort="Canepa, Letizia" uniqKey="Canepa L" first="Letizia" last="Canepa">Letizia Canepa</name><affiliation><nlm:affiliation>Clinica Ematologica, A.O.U. San Martino di Genova, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Fragasso, Alberto" sort="Fragasso, Alberto" uniqKey="Fragasso A" first="Alberto" last="Fragasso">Alberto Fragasso</name><affiliation><nlm:affiliation>Unità Operativa di Oncoematologia, Ospedale di Matera, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Leyvraz, Serge" sort="Leyvraz, Serge" uniqKey="Leyvraz S" first="Serge" last="Leyvraz">Serge Leyvraz</name><affiliation><nlm:affiliation>Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Langer, Christian" sort="Langer, Christian" uniqKey="Langer C" first="Christian" last="Langer">Christian Langer</name><affiliation><nlm:affiliation>Klinik für Innere Medizin III, Ulm, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ezaydi, Yousef" sort="Ezaydi, Yousef" uniqKey="Ezaydi Y" first="Yousef" last="Ezaydi">Yousef Ezaydi</name><affiliation><nlm:affiliation>Royal Hallamshire Hospital, Sheffield, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Vogl, Dan T" sort="Vogl, Dan T" uniqKey="Vogl D" first="Dan T" last="Vogl">Dan T. Vogl</name><affiliation><nlm:affiliation>Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Giraldo Castellano, Pilar" sort="Giraldo Castellano, Pilar" uniqKey="Giraldo Castellano P" first="Pilar" last="Giraldo-Castellano">Pilar Giraldo-Castellano</name><affiliation><nlm:affiliation>CIBER Enfermedades Raras (CIBERER), Translational Research Unit, Miguel Servet University Hospital, Zaragoza, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Yoon, Sung Soo" sort="Yoon, Sung Soo" uniqKey="Yoon S" first="Sung-Soo" last="Yoon">Sung-Soo Yoon</name><affiliation><nlm:affiliation>Seoul National University Hospital, Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Zarnitsky, Charles" sort="Zarnitsky, Charles" uniqKey="Zarnitsky C" first="Charles" last="Zarnitsky">Charles Zarnitsky</name><affiliation><nlm:affiliation>Rhumatologie Nord, Hôpital J. Monod, Le Havre, France.</nlm:affiliation></affiliation></author><author><name sortKey="Escoffre Barbe, Martine" sort="Escoffre Barbe, Martine" uniqKey="Escoffre Barbe M" first="Martine" last="Escoffre-Barbe">Martine Escoffre-Barbe</name><affiliation><nlm:affiliation>CHRU Hôpital de Pontchaillou, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lemieux, Bernard" sort="Lemieux, Bernard" uniqKey="Lemieux B" first="Bernard" last="Lemieux">Bernard Lemieux</name><affiliation><nlm:affiliation>CHUM Hôpital Notre-Dame, Montreal, QUE, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Song, Kevin" sort="Song, Kevin" uniqKey="Song K" first="Kevin" last="Song">Kevin Song</name><affiliation><nlm:affiliation>Vancouver General Hospital, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Bahlis, Nizar Jacques" sort="Bahlis, Nizar Jacques" uniqKey="Bahlis N" first="Nizar Jacques" last="Bahlis">Nizar Jacques Bahlis</name><affiliation><nlm:affiliation>Tom Baker Cancer Centre - University of Calgary, Calgary, AL, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Guo, Shien" sort="Guo, Shien" uniqKey="Guo S" first="Shien" last="Guo">Shien Guo</name><affiliation><nlm:affiliation>Evidera, Lexington, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Monzini, Mara Silva" sort="Monzini, Mara Silva" uniqKey="Monzini M" first="Mara Silva" last="Monzini">Mara Silva Monzini</name><affiliation><nlm:affiliation>Celgene Corporation, Summit, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ervin Haynes, Annette" sort="Ervin Haynes, Annette" uniqKey="Ervin Haynes A" first="Annette" last="Ervin-Haynes">Annette Ervin-Haynes</name><affiliation><nlm:affiliation>Celgene Corporation, Summit, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Houck, Vanessa" sort="Houck, Vanessa" uniqKey="Houck V" first="Vanessa" last="Houck">Vanessa Houck</name><affiliation><nlm:affiliation>Celgene Corporation, Summit, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Facon, Thierry" sort="Facon, Thierry" uniqKey="Facon T" first="Thierry" last="Facon">Thierry Facon</name><affiliation><nlm:affiliation>Hôpital Claude Huriez, Lille, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:25769541</idno><idno type="pmid">25769541</idno><idno type="doi">10.3324/haematol.2014.120121</idno><idno type="wicri:Area/PubMed/Corpus">000087</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.</title><author><name sortKey="Delforge, Michel" sort="Delforge, Michel" uniqKey="Delforge M" first="Michel" last="Delforge">Michel Delforge</name><affiliation><nlm:affiliation>Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium michel.delforge@uzleuven.be.</nlm:affiliation></affiliation></author><author><name sortKey="Minuk, Leonard" sort="Minuk, Leonard" uniqKey="Minuk L" first="Leonard" last="Minuk">Leonard Minuk</name><affiliation><nlm:affiliation>London Health Sciences Centre, London, ON, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Eisenmann, Jean Claude" sort="Eisenmann, Jean Claude" uniqKey="Eisenmann J" first="Jean-Claude" last="Eisenmann">Jean-Claude Eisenmann</name><affiliation><nlm:affiliation>Hôpital Emile Muller, Mulhouse, France.</nlm:affiliation></affiliation></author><author><name sortKey="Arnulf, Bertrand" sort="Arnulf, Bertrand" uniqKey="Arnulf B" first="Bertrand" last="Arnulf">Bertrand Arnulf</name><affiliation><nlm:affiliation>Hôpital Saint-Louis, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Canepa, Letizia" sort="Canepa, Letizia" uniqKey="Canepa L" first="Letizia" last="Canepa">Letizia Canepa</name><affiliation><nlm:affiliation>Clinica Ematologica, A.O.U. San Martino di Genova, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Fragasso, Alberto" sort="Fragasso, Alberto" uniqKey="Fragasso A" first="Alberto" last="Fragasso">Alberto Fragasso</name><affiliation><nlm:affiliation>Unità Operativa di Oncoematologia, Ospedale di Matera, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Leyvraz, Serge" sort="Leyvraz, Serge" uniqKey="Leyvraz S" first="Serge" last="Leyvraz">Serge Leyvraz</name><affiliation><nlm:affiliation>Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Langer, Christian" sort="Langer, Christian" uniqKey="Langer C" first="Christian" last="Langer">Christian Langer</name><affiliation><nlm:affiliation>Klinik für Innere Medizin III, Ulm, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Ezaydi, Yousef" sort="Ezaydi, Yousef" uniqKey="Ezaydi Y" first="Yousef" last="Ezaydi">Yousef Ezaydi</name><affiliation><nlm:affiliation>Royal Hallamshire Hospital, Sheffield, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Vogl, Dan T" sort="Vogl, Dan T" uniqKey="Vogl D" first="Dan T" last="Vogl">Dan T. Vogl</name><affiliation><nlm:affiliation>Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Giraldo Castellano, Pilar" sort="Giraldo Castellano, Pilar" uniqKey="Giraldo Castellano P" first="Pilar" last="Giraldo-Castellano">Pilar Giraldo-Castellano</name><affiliation><nlm:affiliation>CIBER Enfermedades Raras (CIBERER), Translational Research Unit, Miguel Servet University Hospital, Zaragoza, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Yoon, Sung Soo" sort="Yoon, Sung Soo" uniqKey="Yoon S" first="Sung-Soo" last="Yoon">Sung-Soo Yoon</name><affiliation><nlm:affiliation>Seoul National University Hospital, Korea.</nlm:affiliation></affiliation></author><author><name sortKey="Zarnitsky, Charles" sort="Zarnitsky, Charles" uniqKey="Zarnitsky C" first="Charles" last="Zarnitsky">Charles Zarnitsky</name><affiliation><nlm:affiliation>Rhumatologie Nord, Hôpital J. Monod, Le Havre, France.</nlm:affiliation></affiliation></author><author><name sortKey="Escoffre Barbe, Martine" sort="Escoffre Barbe, Martine" uniqKey="Escoffre Barbe M" first="Martine" last="Escoffre-Barbe">Martine Escoffre-Barbe</name><affiliation><nlm:affiliation>CHRU Hôpital de Pontchaillou, Rennes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Lemieux, Bernard" sort="Lemieux, Bernard" uniqKey="Lemieux B" first="Bernard" last="Lemieux">Bernard Lemieux</name><affiliation><nlm:affiliation>CHUM Hôpital Notre-Dame, Montreal, QUE, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Song, Kevin" sort="Song, Kevin" uniqKey="Song K" first="Kevin" last="Song">Kevin Song</name><affiliation><nlm:affiliation>Vancouver General Hospital, Vancouver, BC, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Bahlis, Nizar Jacques" sort="Bahlis, Nizar Jacques" uniqKey="Bahlis N" first="Nizar Jacques" last="Bahlis">Nizar Jacques Bahlis</name><affiliation><nlm:affiliation>Tom Baker Cancer Centre - University of Calgary, Calgary, AL, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Guo, Shien" sort="Guo, Shien" uniqKey="Guo S" first="Shien" last="Guo">Shien Guo</name><affiliation><nlm:affiliation>Evidera, Lexington, MA, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Monzini, Mara Silva" sort="Monzini, Mara Silva" uniqKey="Monzini M" first="Mara Silva" last="Monzini">Mara Silva Monzini</name><affiliation><nlm:affiliation>Celgene Corporation, Summit, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Ervin Haynes, Annette" sort="Ervin Haynes, Annette" uniqKey="Ervin Haynes A" first="Annette" last="Ervin-Haynes">Annette Ervin-Haynes</name><affiliation><nlm:affiliation>Celgene Corporation, Summit, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Houck, Vanessa" sort="Houck, Vanessa" uniqKey="Houck V" first="Vanessa" last="Houck">Vanessa Houck</name><affiliation><nlm:affiliation>Celgene Corporation, Summit, NJ, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Facon, Thierry" sort="Facon, Thierry" uniqKey="Facon T" first="Thierry" last="Facon">Thierry Facon</name><affiliation><nlm:affiliation>Hôpital Claude Huriez, Lille, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Haematologica</title><idno type="eISSN">1592-8721</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (administration & dosage)</term><term>Cross-Sectional Studies</term><term>Dexamethasone (administration & dosage)</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term><term>Melphalan (administration & dosage)</term><term>Multiple Myeloma (diagnosis)</term><term>Multiple Myeloma (drug therapy)</term><term>Multiple Myeloma (psychology)</term><term>Prednisone (administration & dosage)</term><term>Quality of Life (psychology)</term><term>Thalidomide (administration & dosage)</term><term>Thalidomide (analogs & derivatives)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dexamethasone</term><term>Melphalan</term><term>Prednisone</term><term>Thalidomide</term></keywords><keywords scheme="MESH" qualifier="administration & dosage" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Thalidomide</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Multiple Myeloma</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Multiple Myeloma</term><term>Quality of Life</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Cross-Sectional Studies</term><term>Female</term><term>Health Status</term><term>Humans</term><term>Male</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexamethasone, and melphalan, prednisone, thalidomide improved patients' health-related quality-of-life from baseline over the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalidomide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeated-measures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and low-dose dexamethasone delays disease progression versus melphalan, prednisone, thalidomide and has been associated with a clinically meaningful improvement in health-related quality-of-life. These results further establish continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone, thalidomide.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">25769541</PMID><DateCreated><Year>2015</Year><Month>6</Month><Day>2</Day></DateCreated><DateCompleted><Year>2016</Year><Month>02</Month><Day>12</Day></DateCompleted><DateRevised><Year>2015</Year><Month>6</Month><Day>6</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1592-8721</ISSN><JournalIssue CitedMedium="Internet"><Volume>100</Volume><Issue>6</Issue><PubDate><Year>2015</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Haematologica</Title><ISOAbbreviation>Haematologica</ISOAbbreviation></Journal><ArticleTitle>Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.</ArticleTitle><Pagination><MedlinePgn>826-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3324/haematol.2014.120121</ELocationID><Abstract><AbstractText>We compared the health-related quality-of-life of patients with newly diagnosed multiple myeloma aged over 65 years or transplant-ineligible in the pivotal, phase III FIRST trial. Patients received: i) continuous lenalidomide and low-dose dexamethasone until disease progression; ii) fixed cycles of lenalidomide and low-dose dexamethasone for 18 months; or iii) fixed cycles of melphalan, prednisone, thalidomide for 18 months. Data were collected using the validated questionnaires (QLQ-MY20, QLQ-C30, and EQ-5D). The analysis focused on the EQ-5D utility value and six domains pre-selected for their perceived clinical relevance. Lenalidomide and low-dose dexamethasone, and melphalan, prednisone, thalidomide improved patients' health-related quality-of-life from baseline over the duration of the study across all pre-selected domains of the QLQ-C30 and EQ-5D. In the QLQ-MY20, lenalidomide and low-dose dexamethasone demonstrated a significantly greater reduction in the Disease Symptoms domain compared with melphalan, prednisone, thalidomide at Month 3, and significantly lower scores for QLQ-MY20 Side Effects of Treatment at all post-baseline assessments except Month 18. Linear mixed-model repeated-measures analyses confirmed the results observed in the cross-sectional analysis. Continuous lenalidomide and low-dose dexamethasone delays disease progression versus melphalan, prednisone, thalidomide and has been associated with a clinically meaningful improvement in health-related quality-of-life. These results further establish continuous lenalidomide and low-dose dexamethasone as a new standard of care for initial therapy of myeloma by demonstrating superior health-related quality-of-life during treatment, compared with melphalan, prednisone, thalidomide.</AbstractText><CopyrightInformation>Copyright© Ferrata Storti Foundation.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Delforge</LastName><ForeName>Michel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Universitair Ziekenhuis Leuven, Campus Gasthuisberg, Leuven, Belgium michel.delforge@uzleuven.be.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minuk</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>London Health Sciences Centre, London, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenmann</LastName><ForeName>Jean-Claude</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Hôpital Emile Muller, Mulhouse, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arnulf</LastName><ForeName>Bertrand</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Hôpital Saint-Louis, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Canepa</LastName><ForeName>Letizia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinica Ematologica, A.O.U. San Martino di Genova, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fragasso</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Unità Operativa di Oncoematologia, Ospedale di Matera, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leyvraz</LastName><ForeName>Serge</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre Hospitalier Universitaire Vaudois (CHUV), Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langer</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Klinik für Innere Medizin III, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ezaydi</LastName><ForeName>Yousef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Royal Hallamshire Hospital, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vogl</LastName><ForeName>Dan T</ForeName><Initials>DT</Initials><AffiliationInfo><Affiliation>Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giraldo-Castellano</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>CIBER Enfermedades Raras (CIBERER), Translational Research Unit, Miguel Servet University Hospital, Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Sung-Soo</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Seoul National University Hospital, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zarnitsky</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Rhumatologie Nord, Hôpital J. Monod, Le Havre, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escoffre-Barbe</LastName><ForeName>Martine</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHRU Hôpital de Pontchaillou, Rennes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lemieux</LastName><ForeName>Bernard</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>CHUM Hôpital Notre-Dame, Montreal, QUE, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Vancouver General Hospital, Vancouver, BC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bahlis</LastName><ForeName>Nizar Jacques</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Tom Baker Cancer Centre - University of Calgary, Calgary, AL, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Shien</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Evidera, Lexington, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monzini</LastName><ForeName>Mara Silva</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Celgene Corporation, Summit, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ervin-Haynes</LastName><ForeName>Annette</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Celgene Corporation, Summit, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houck</LastName><ForeName>Vanessa</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Celgene Corporation, Summit, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Facon</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Hôpital Claude Huriez, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>ENG</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>Mar</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Haematologica</MedlineTA><NlmUniqueID>0417435</NlmUniqueID><ISSNLinking>0390-6078</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>4Z8R6ORS6L</RegistryNumber><NameOfSubstance UI="D013792">Thalidomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical><Chemical><RegistryNumber>F0P408N6V4</RegistryNumber><NameOfSubstance UI="C467567">lenalidomide</NameOfSubstance></Chemical><Chemical><RegistryNumber>Q41OR9510P</RegistryNumber><NameOfSubstance UI="D008558">Melphalan</NameOfSubstance></Chemical><Chemical><RegistryNumber>VB0R961HZT</RegistryNumber><NameOfSubstance UI="D011241">Prednisone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 1997 Apr;97(1):29-37</RefSource><PMID Version="1">9136939</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Cancer Inst. 1993 Mar 3;85(5):365-76</RefSource><PMID Version="1">8433390</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 1996 Mar;92(3):604-13</RefSource><PMID Version="1">8616024</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Care. 1997 Nov;35(11):1095-108</RefSource><PMID Version="1">9366889</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Br J Haematol. 1999 Mar;104(3):605-11</RefSource><PMID Version="1">10086801</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2005 Feb;74(2):136-43</RefSource><PMID Version="1">15654905</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Qual Life Res. 2005 Aug;14(6):1523-32</RefSource><PMID Version="1">16110932</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2006 Mar 11;367(9513):825-31</RefSource><PMID Version="1">16530576</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Pharmacoeconomics. 2007;25(5):365-84</RefSource><PMID Version="1">17488136</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2007 May 20;25(15):1993-9</RefSource><PMID Version="1">17420512</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Cancer. 2007 Jul;43(11):1670-8</RefSource><PMID Version="1">17574838</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet. 2007 Oct 6;370(9594):1209-18</RefSource><PMID Version="1">17920916</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Nov 22;357(21):2123-32</RefSource><PMID Version="1">18032762</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2007 Nov 22;357(21):2133-42</RefSource><PMID Version="1">18032763</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2008 Mar 1;111(5):2521-6</RefSource><PMID Version="1">17901246</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2008 Aug 28;359(9):906-17</RefSource><PMID Version="1">18753647</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2009 Aug;83(2):139-48</RefSource><PMID Version="1">19284418</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Aug 1;27(22):3664-70</RefSource><PMID Version="1">19451428</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2009 Nov;23(11):2147-52</RefSource><PMID Version="1">19626046</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2010 Jan;11(1):29-37</RefSource><PMID Version="1">19853510</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2010 Apr;84(4):345-53</RefSource><PMID Version="1">20041946</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jul 1;28(19):3160-6</RefSource><PMID Version="1">20516439</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Psychooncology. 2011 Jan;20(1):88-97</RefSource><PMID Version="1">20187072</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Clin Cancer Res. 2011 Mar 15;17(6):1253-63</RefSource><PMID Version="1">21411441</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2011 Mar 17;364(11):1046-60</RefSource><PMID Version="1">21410373</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2011 Apr;25(4):689-96</RefSource><PMID Version="1">21233832</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Blood. 2011 Aug 4;118(5):1239-47</RefSource><PMID Version="1">21670471</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2011 Oct;87(4):330-7</RefSource><PMID Version="1">21668504</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Hematol. 2011 Dec;90(12):1427-39</RefSource><PMID Version="1">21472373</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2012 Jul;89(1):16-27</RefSource><PMID Version="1">22469559</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2012 Oct;89(4):311-9</RefSource><PMID Version="1">22762785</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Eur J Haematol. 2012 Dec;89(6):437-57</RefSource><PMID Version="1">22985406</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Natl Compr Canc Netw. 2013 Jan 1;11(1):43-9</RefSource><PMID Version="1">23307980</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Haematologica. 2013 May;98(5):784-8</RefSource><PMID Version="1">23242595</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Ann Oncol. 2013 Oct;24 Suppl 6:vi133-7</RefSource><PMID Version="1">23956208</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2013 Oct;27(10):1959-69</RefSource><PMID Version="1">23783393</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2014 May;28(5):981-92</RefSource><PMID Version="1">24177258</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leuk Lymphoma. 2014 Jul;55(7):1489-97</RefSource><PMID Version="1">24144308</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2014 Sep 4;371(10):906-17</RefSource><PMID Version="1">25184863</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Leukemia. 2014 May;28(5):1122-8</RefSource><PMID Version="1">24157580</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncol Nurs Forum. 2001 Aug;28(7):1163-71</RefSource><PMID Version="1">11517849</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Med Oncol. 2001;18(1):65-77</RefSource><PMID Version="1">11778972</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>Haematologica. 2015 Jun;100(6):704-5</RefSource><PMID Version="1">26034111</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006304" MajorTopicYN="Y">Health Status</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008558" MajorTopicYN="N">Melphalan</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009101" MajorTopicYN="N">Multiple Myeloma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011241" MajorTopicYN="N">Prednisone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="Y">Quality of Life</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013792" MajorTopicYN="N">Thalidomide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4450629</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>11</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>06</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>2</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25769541</ArticleId><ArticleId IdType="pii">haematol.2014.120121</ArticleId><ArticleId IdType="doi">10.3324/haematol.2014.120121</ArticleId><ArticleId IdType="pmc">PMC4450629</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/France/explor/LeHavreV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000087 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000087 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/France
|area= LeHavreV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:25769541
|texte= Health-related quality-of-life in patients with newly diagnosed multiple myeloma in the FIRST trial: lenalidomide plus low-dose dexamethasone versus melphalan, prednisone, thalidomide.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:25769541" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a LeHavreV1
| This area was generated with Dilib version V0.6.25. |  |